Urological Devices – Market Insights – United States

Driven by product innovation, rising kidney stone prevalence, and an aging population, the market for US urological devices will grow at a modest rate through 2032 despite the significant impact of the COVID-19 pandemic during 2020-2022. Going forward, favorable demographic trends, an increasing prevalence of obesity, adoption of premium devices, and the growing availability of less invasive treatment options will support the growth of urology procedure volumes. Moreover, the continued shift toward value-based health care in the US will drive demand for minimally invasive treatments that not only provide improved efficacy, but also reduced postoperative pain and shorter recovery periods.

This Medtech 360 Report provides comprehensive data and analysis on the state of the US urological device market from 2019 through 2032.

Emerging technologies and innovative products will grow in popularity at the expense of competing treatment options.

What are the most recent technological innovations in the urological device market?

How will these innovations affect the efficacy and utilization of procedures in these segments?

How will the growing preference for ureteroscopy affect the stone management device market?

What role does strong clinical evidence play in the adoption of new technologies and devices?

What insights do physicians currently provide regarding prevailing trends in the urology space?

Minimally invasive treatment volumes will grow strongly.

What factors contribute to the increase of minimally invasive treatments?

How have minimally invasive treatment options changed the BPH device market?

Which market segments will see the greatest adoption of minimally invasive treatments?

What is the impact of Aquablation on the US urological device market?

Mergers and acquisitions have been altering the competitive landscape.

What are the most relevant recent acquisitions to affect the market?

How will market shares and product portfolios be affected as a result of these acquisitions?

Ongoing clinical studies and research continue to affect procedure trends, and thus device trends.

What do recent studies indicate regarding the outlook of existing techniques for treating prostate cancer, kidney stones, and BPH?

Premium devices and their adoption will influence market trends.

Which markets are going to be affected by preference for premium variants of devices?

What circumstances hinder the uptake of premium devices in the US?

Table of contents